The Motley Fool
12 Jul 2026, 21:38 UTC · 18w ago
An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run
Impact · against what's priced in
ADPT is showing strong operational momentum with a 35% revenue increase and raised full-year guidance, suggesting an accelerating path to profitability. The insider sale is a non-event as it was pre-planned and represents a small fraction of the officer's total holdings.
- ADPT+0.50
No priced-in read yet





